European Guidelines for Obesity Management in Adults

Volkan Yumuk, Constantine Tsigos, Martin Fried, Karin Schindler, Luca Busetto, Dragan Micic, Hermann Toplak, Obesity Management Task Force of the European Association for the Study of Obesity, Volkan Yumuk, Constantine Tsigos, Martin Fried, Karin Schindler, Luca Busetto, Dragan Micic, Hermann Toplak, Obesity Management Task Force of the European Association for the Study of Obesity

Abstract

Obesity is a chronic metabolic disease characterised by an increase of body fat stores. It is a gateway to ill health, and it has become one of the leading causes of disability and death, affecting not only adults but also children and adolescents worldwide. In clinical practice, the body fatness is estimated by BMI, and the accumulation of intra-abdominal fat (marker for higher metabolic and cardiovascular disease risk) can be assessed by waist circumference. Complex interactions between biological, behavioural, social and environmental factors are involved in regulation of energy balance and fat stores. A comprehensive history, physical examination and laboratory assessment relevant to the patient's obesity should be obtained. Appropriate goals of weight management emphasise realistic weight loss to achieve a reduction in health risks and should include promotion of weight loss, maintenance and prevention of weight regain. Management of co-morbidities and improving quality of life of obese patients are also included in treatment aims. Balanced hypocaloric diets result in clinically meaningful weight loss regardless of which macronutrients they emphasise. Aerobic training is the optimal mode of exercise for reducing fat mass while a programme including resistance training is needed for increasing lean mass in middle-aged and overweight/obese individuals. Cognitive behavioural therapy directly addresses behaviours that require change for successful weight loss and weight loss maintenance. Pharmacotherapy can help patients to maintain compliance and ameliorate obesity-related health risks. Surgery is the most effective treatment for morbid obesity in terms of long-term weight loss. A comprehensive obesity management can only be accomplished by a multidisciplinary obesity management team. We conclude that physicians have a responsibility to recognise obesity as a disease and help obese patients with appropriate prevention and treatment. Treatment should be based on good clinical care, and evidence-based interventions; should focus on realistic goals and lifelong multidisciplinary management.

© 2015 S. Karger GmbH, Freiburg.

Figures

Fig. 1
Fig. 1
Obesity prevalence in adults in Europe (Source: WHO 2014 data).
Fig. 2
Fig. 2
Algorithm for the assessment and stepwise management of overweight and obese adults. *BMI and WC cut-off points are different for some ethnic groups (see text).

References

    1. Frühbeck G, Toplak H, Woodward E, Yumuk V, Maislos M, Oppert JM. Obesity: the gateway to ill health – an EASO position statement on a rising public health, clinical and scientific challenge in Europe. Obes Facts. 2013;6:117–120.
    1. World Health Organization . WHO fact sheet No 311. Geneva: WHO; 2015. Obesity and Overweight. (last accessed November 30, 2015).
    1. World Health Organization . World Health Statistics 2015. Geneva: WHO; 2015. pp. 101–111. (last accessed November 30, 2015).
    1. Kelly T, Yang W, Chen CS, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond) 2008;32:1431–1437.
    1. Finer N. Medical consequences of obesity. Medicine. 2015;43:88–93.
    1. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, Mullany EC, Biryukov S, Abbafati C, Abera SF, Abraham JP, Abu-Rmeileh NM, Achoki T, AlBuhairan FS, Alemu ZA, Alfonso R, Ali MK, Ali R, Guzman NA, Ammar W, Anwari P, Banerjee A, Barquera S, Basu S, Bennett DA, Bhutta Z, Blore J, Cabral N, Nonato IC, Chang JC, Chowdhury R, Courville KJ, Criqui MH, Cundiff DK, Dabhadkar KC, Dandona L, Davis A, Dayama A, Dharmaratne SD, Ding EL, Durrani AM, Esteghamati A, Farzadfar F, Fay DF, Feigin VL, Flaxman A, Forouzanfar MH, Goto A, Green MA, Gupta R, Hafezi-Nejad N, Hankey GJ, Harewood HC, Havmoeller R, Hay S, Hernandez L, Husseini A, Idrisov BT, Ikeda N, Islami F, Jahangir E, Jassal SK, Jee SH, Jeffreys M, Jonas JB, Kabagambe EK, Khalifa SE, Kengne AP, Khader YS, Khang YH, Kim D, Kimokoti RW, Kinge JM, Kokubo Y, Kosen S, Kwan G, Lai T, Leinsalu M, Li Y, Liang X, Liu S, Logroscino G, Lotufo PA, Lu Y, Ma J, Mainoo NK, Mensah GA, Merriman TR, Mokdad AH, Moschandreas J, Naghavi M, Naheed A, Nand D, Narayan KM, Nelson EL, Neuhouser ML, Nisar MI, Ohkubo T, Oti SO, Pedroza A, Prabhakaran D, Roy N, Sampson U, Seo H, Sepanlou SG, Shibuya K, Shiri R, Shiue I, Singh GM, Singh JA, Skirbekk V, Stapelberg NJ, Sturua L, Sykes BL, Tobias M, Tran BX, Trasande L, Toyoshima H, van de Vijver S, Vasankari TJ, Veerman JL, Velasquez-Melendez G, Vlassov VV, Vollset SE, Vos T, Wang C, Wang X, Weiderpass E, Werdecker A, Wright JL, Yang YC, Yatsuya H, Yoon J, Yoon SJ, Zhao Y, Zhou M, Zhu S, Lopez AD, Murray CJ, Gakidou E. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384:766–781.
    1. WHO Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation. Geneva, WHO Technical Report Series 894, 2000.
    1. James WP. The epidemiology of obesity: the size of the problem. J Intern Med. 2008;263:336–352.
    1. Zhu S, Wang Z, Heshka S, Heo M, Faith MS, Heymsfield SB. Waist circumference and Obesity associated risk factors among whites in the third National Health and Nutrition Examination Survey: clinical action thresholds. Am J Clin Nutr. 2002;76:743–749.
    1. Alberti KG, Zimmet PZ, Shaw J. The metabolic syndrome – a new worldwide definition. Lancet. 2005;366:1059–1062.
    1. Yanovski SZ, Yanovski JA. Obesity. N Engl J Med. 2002;346:591–602.
    1. Haslam DW, James WP. Obesity. Lancet. 2005;366:1197–1209.
    1. Farooqi S, O'Rahilly S. Genetics of obesity in humans. Endocr Rev. 2006;27:710–718.
    1. Kyrou I, Chrousos GP, Tsigos C. Stress, visceral obesity, and metabolic complications. Ann N Y Acad Sci. 2006;1083:77–110.
    1. Branca F, Nikogosian H, Lobstein T, editors. The challenge of Obesity in the WHO European Region and the Strategies for Response: Summary. Copenhagen: WHO Regional Office for Europe; 2007.
    1. Ailhaud G. Adipose tissue as a secretory organ: from adipogenesis to the metabolic syndrome. C R Biol. 2006;329:570–577.
    1. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006;6:772–783.
    1. Buhmann H, le Roux CW, Bueter M. The gut brain axis in obesity. Best Pract Res Clin Gastroenterol. 2014;28:559–571.
    1. Holtmann G, Talley NJ. The stomach brain axis. Best Pract Res Clin Gastroenterol. 2014;28:967–979.
    1. Gerard P. Gut microbiota and obesity. Cell Mol Life Sci. 2015 DOI 10.1007/s00018-015-2061-5.
    1. Tilg H, Adolph TE. Influence of the human intestinal microbiome on obesity and metabolic dysfunction. Curr Opin Pediatr. 2015;27:496–501.
    1. Cypess AM, Lehman S, Williams G, Tal I, Rodman D, Goldfine AB, Kuo FC, Palmer EL, Tseng Y-H, Doria A, Kolodny GM, Kahn R. Identification and importance of brown adipose tissue in adult humans. N Engl J Med. 2009;360:1509–1517.
    1. Virtanen KA, Lidell ME, Orava J, Heglind M, Westergren R, Niemi T, Taittonen M, Laine J, Savisto N-J, Enerback S, Nuutila P. Functional brown adipose tissue in healthy adults. N Engl J Med. 2009;360:1518–1525.
    1. Butler PW, Mentuccia D, Celi FS. Stimulating brown fat: a potential future therapeutic approach for obesity and insulin resistance? Heart Metab. 2010;48:19–22.
    1. National Institutes of Health . NHLBI Obesity Education Initiative Expert Panel on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Bethesda: NIH; 2000. The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. (last accessed November 30, 2015).
    1. National Institute for Health and care Excellence . Obesity: Identification, Assessment and Management of Overweight and Obesity in Children, Young People and Adults. London: NICE; 2014. (last accessed November 30, 2015).
    1. Kushner RF. Clinical assessment and management of adult obesity. Circulation. 2012;126:2870–2877.
    1. Silver HJ, Welch EB, Avison MJ, Niswender KD. Imaging body composition in obesity and weight loss: challenges and opportunities. Diabetes Metab Syndr Obes. 2010;3:337–347.
    1. Bolanowski M, Nilsson BE. Assessment of human body composition using dual-energy x-ray absorptiometry and bioelectrical impedance analysis. Med Sci Monit. 2001;7:1029–1033.
    1. Cornier M-A, Després J-P, Davis N, Grossniklaus DA, Klein S, Lamarche B, Lopez-Jimenez F, Rao G, St-Onge M-P, Towfighi A, Poirier P, on behalf of the American Heart Association Obesity Committee of the Council on Nutrition Physical Activity and Metabolism Council on Arteriosclerosis Thrombosis and Vascular Biology Council on Cardiovascular Disease in the Young Council on Cardiovascular Radiology and Intervention Council on Cardiovascular Nursing Council on Epidemiology and Prevention Council on the Kidney in Cardiovascular Disease and Stroke Council Assessing adiposity: a scientific statement from the American Heart Association. Circulation. 2011;124:1996–2019.
    1. Yumuk V, Frühbeck G, Oppert JM, Woodward E, Toplak H, for the Executive Committee of the European Association for the Study of Obesity An EASO position statement on multidisciplinary obesity management in adults. Obes Facts. 2014;7:96–101.
    1. Slentz CA, Duscha BD, Johnson JL, Ketchum K, Aiken LB, Samsa GP, Houmard JA, Bales CW, Kraus WE. Effects of the amount of exercise on body weight, body composition, and measures of central obesity: STRRIDE – a randomized controlled study. Arch Intern Med. 2004;164:31–39.
    1. Pietrobelli A, Heymsfield SB. Establishing body composition in obesity. J Endocrinol Invest. 2002;25:884–892.
    1. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, Diabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.
    1. Blundell JE, Dulloo AG, Salvador J, Frühbeck G, on behalf of the EASO SAB Working Group on BMI Beyond BMI – phenotyping the obesities. Obes Facts. 2014;7:322–328.
    1. Schwarz PE, Lindström J, Kissimova-Scarbeck K, Szybinski Z, Barengo NC, Peltonen M, Tuomilehto J. The European perspective of type 2 diabetes prevention: diabetes in Europe – prevention using lifestyle, physical activity and nutritional intervention (DE-PLAN) project. Exp Clin Endocrinol Diabetes. 2008;116:167–172.
    1. Hainer V, Toplak H, Mitrakou A. Treatment modalities of obesity: What fits whom? Diabetes Care. 2008;31((suppl 2)):S269–S277.
    1. Sampsel S, May J. Assessment and management of obesity and comorbid conditions. Dis Manag. 2007;1:252–265.
    1. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, Hu FB, Hubbard VS, Jakicic JM, Kushner RF, Loria CM, Millen BE, Nonas CA, Pi-Sunyer FX, Stevens J, Stevens VJ, Wadden TA, Wolfe BM, Yanovski SZ, Jordan HS, Kendall KA, Lux LJ, Mentor-Marcel R, Morgan LC, Trisolini MG, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC, Jr, Tomaselli GF, American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Obesity Society 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129((suppl 2)):S102–S138. Erratum in Circulation 2014;129(suppl 2):S139–140.
    1. World Health Organization . Report of a WHO Consultation (WHO Technical Report Series 894). Geneva: WHO; 1998. Obesity: Preventing and Managing the Global Epidemic. (last accessed November 30, 2015).
    1. Lahti-Koski M, Männistö S, Pietinen P, Vartiainen E. Prevalence of weight cycling and its relation to health indicators in Finland. Obes Res. 2005;13:333–341.
    1. Marchesini G, Cuzzolaro M, Mannucci E, DalleGrave R, Gennaro M, Tomasi F, Barantani EG, Melchionda N, QUOVADIS Study Group Weight cycling in treatment-seeking obese persons: data from the QUOVADIS study. Int J Obes Relat Metab Disord. 2004;28:1456–1462.
    1. Anderson JW, Konz EC, Frederich RC, Wood CL. Long-term weight-loss maintenance: a meta-analysis of US studies. Am J Clin Nutr. 2001;74:579–584.
    1. Christie D, Channon S. The potential for motivational interviewing to improve outcomes in the management of diabetes and obesity in paediatric and adult populations: a clinical review. Diabetes, Obes Metab. 2014;16:381–387.
    1. Armstrong MJ, Mottershead TA, Ronksley PE, Sigal RJ, Campbell TS, Hemmelgarn BR. Motivational interviewing to improve weight loss in overweight and/or obese patients: a systematic review and meta-analysis of randomized controlled trials. Obes Rev. 2011;12:709–723.
    1. Dansinger ML, Tatsioni A, Wong JB, Chung M, Balk EM. Meta-analysis: the effect of dietary counseling for weight loss. Ann Intern Med. 2007;147:41–50.
    1. Astrup A, Grunwald GK, Melanson EL, Saris WH, Hill JO. The role of low-fat diets in body weight control: a meta-analysis of ad libitum dietary intervention studies. Int J Obes Relat Metab Disord. 2000;24:1545–1552.
    1. Pirozzo S, Summerbell C, Cameron C, Glasziou P. Advice on low-fat diets for obesity. Cochrane Database Syst Rev. 2002;2:CD003640.
    1. Sacks FM, Bray GA, Carey VJ, Smith SR, Ryan DH, Anton SD, McManus K, Champagne CM, Bishop LM, Laranjo N, Leboff MS, Rood JC, de Jonge L, Greenway FL, Loria CM, Obarzanek E, Williamson DA. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med. 2009;360:859–873.
    1. Larsen TM, Dalskov S-M, van Baak M, Jebb SA, Papadaki A, Pfeiffer AFH, Martinez JA, Handjieva-Darlenska T, Kunešová M, Pihlsgård M, Stender S, Holst C, Saris WHM, Astrup A, for the Diet and Genes (Diogenes) Project Diets with high or low protein content and glycemic index for weight-loss maintenance. N Engl J Med. 2010;363:2102–2113.
    1. Shai I, Schwarzfuchs D, Henkin Y, Shahar DR, Witkow S, Greenberg I, Golan R, Fraser D, Bolotin A, Vardi H, Tangi-Rozental O, Zuk-Ramot R, Sarusi B, Brickner D, Schwartz Z, Sheiner E, Marko R, Katorza E, Thiery J, Fiedler GM, Bluher M, Stumvoll M, Stampfer MJ, for the Dietary Intervention Randomized Controlled Trial (DIRECT) Group Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med. 2008;359:229–241.
    1. Dernini S, Berry EM. Mediterranean diet: from a healthy diet to a sustainable dietary pattern. Front Nutr. 2015;2:1–6.
    1. Estruch R, Ros E, Salas-Salvadó J, Covas M-I, Corella D, Arós F, Gómez-Gracia E, Ruiz-Gutiérrez V, Fiol M, Lapetra J, Lamuela-Raventos RM, Serra-Majem L, Pintó X, Basora J, Muñoz MA, Sorlí JV, Martínez JA, Martínez-González MA, for the PREDIMED Study Investigators Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368:1279–1290.
    1. Ayyad C, Andersen T. Long-term efficacy of dietary treatment of obesity: a systematic review of studies published between 1931 and 1999. Obes Rev. 2000;1:113–119.
    1. Rössner S. Treatment: Diet. In: Bjorntorp P, editor. International Textbook of Obesity. Sussex: Wiley & Sons; 2001. pp. 441–449.
    1. Dubnov-Raz G, Berry EM. The dietary treatment of obesity. Endocrinol Metab Clin N Am. 2008;37:873–886.
    1. Tsai AG, Wadden TA. The evolution of very-low-calorie diets: an update and meta-analysis. Obesity (Silver Spring) 2006;14:1283–1293.
    1. Heymsfield SB, van Mierlo CA, van der Knaap HC, Heo M, Frier HI. Weight management using a meal replacement strategy: meta and pooling analysis from six studies. Int J Obes Relat Metab Disord. 2003;27:537–549.
    1. Greenwald A. Current nutritional treatments of obesity. Adv Psychosom Med. 2006;27:24–41.
    1. Willis LH, Slentz CA, Bateman LA, Shields AT, Piner LW, Bales CW, Houmard JA, Kraus WE. Effects of aerobic and/or resistance training on body mass and fat mass in overweight or obese adults. J Appl Physiol. 2012;113:1831–1837.
    1. Geliebter A, Christopher N, Ochner CN, Dambkowski CL, Hashim SA. Obesity-related hormones and metabolic risk factors: a randomized trial of diet plus either strength or aerobic training versus diet alone in overweight participants. J Diabetes Obes. 2015;1:1–7.
    1. Poirier P, Després JP. Exercise in weight management of obesity. Cardiol Clin. 2001;19:459–470.
    1. Kay SJ, Fiatarone Singh MA. The influence of physical activity on abdominal fat: a systematic review of the literature. Obes Rev. 2006;7:183–200.
    1. Lee S, Kuk JL, Davidson LE, Hudson R, Kilpatrick K, Graham TE, Ross R. Exercise without weight loss is an effective strategy for obesity reduction in obese individuals with and without type 2 diabetes. J Appl Physiol. 2005;99:1220–1225.
    1. Ross R, Janssen I, Dawson J, Kungl AM, Kuk JL, Wong SL, Nguyen-Duy TB, Lee S, Kilpatrick K, Hudson R. Exercise-induced reduction in obesity and insulin resistance in women: a randomized controlled trial. Obes Res. 2004;12:789–798.
    1. Swift DL, Johannsen NM, Lavie CJ, Earnest CP, Church TS. The role of exercise and physical activity in weight loss and maintenance. Prog Cardiovasc Dis. 2014;56:441–447.
    1. Jakicic JM, Otto AD. Physical activity considerations for the treatment and prevention of obesity. Am J Clin Nutr. 2005;82((suppl 1)):226S–229S.
    1. Sharma M. Behavioural interventions for preventing and treating obesity in adults. Obes Rev. 2007;8:441–449.
    1. Lang A, Froelicher ES. Management of overweight and obesity in adults: behavioral intervention for long-term weight loss and maintenance. Eur J Cardiovasc Nurs. 2006;5:102–114.
    1. Moffitt R, Haynes A, Mohr P. Treatment beliefs and preferences for psychological therapies for weight management. J Clin Psychol. 2015;71:584–596.
    1. Toplak H, Woodward E, Yumuk V, Oppert JM, Halford JCG, Frühbeck G. 2014 EASO position statement on the use of anti-obesity drugs. Obes Facts. 2015;8:166–174.
    1. Pucci A, Finer N. New medications for treatment of obesity: metabolic and cardiovascular effects. Can J Cardiol. 2015;31:142–152.
    1. Apovian CM, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, Pagotto U, Ryan DH, Still CD. Pharmacological management of obesity: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100:342–362.
    1. Bray GA. Medical treatment of obesity: the past, the present and the future. Best Pract Res Clin Gastroenterol. 2014;28:665–684.
    1. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. Xenical in the Prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155–161.
    1. Toplak H, Ziegler O, Keller U, Hamann A, Godin C, Wittert G, Zanella MT, Zúñiga-Guajardo S, Van Gaal L. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance. Diabetes Obes Metab. 2005;7:699–708.
    1. Ballinger A, Peikin SR. Orlistat: its current status as an anti-obesity drug. Eur J Pharmacol. 2002;440:109–117.
    1. Thomsen WJ, Grottick AJ, Menzaghi F, Reyes-Saldana H, Espitia S, Yuskin D, Whelan K, Martin M, Morgan M, Chen W, Al-Shamma H, Smith B, Chalmers D, Behan D. Lorcaserin: a novel selective human 5-hydroxytryptamine 2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther. 2008;325:577–587.
    1. Chan EW, He Y, Chui CS, Wong AY, Lau WC, Wong IC. Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs. Obes Rev. 2013;14:383–392.
    1. Fujioka K. Safety and tolerability of medications approved for chronic weight management. Obesity (Silver Spring) 2015;23((suppl 1)):S7–S11.
    1. Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, Bays H, Shanahan WR, Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group Multicenter, placebo controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363:245–256.
    1. O'Neil PM, Smith SR, Weissman NJ, Fidler MC, Sanchez M, Zhang J, Raether B, Anderson CM, Shanahan WR. Randomized placebo controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring) 2012;20:1426–1436.
    1. Fidler MC, Sanchez M, Raether B, Weissman NJ, Smith SR, Shanahan WR, Anderson CM, BLOSSOM Clinical Trial Group A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96:3067–3077.
    1. Weissman NJ, Sanchez M, Koch GG, Smith SR, Shanahan WR, Anderson CM. Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials. Circ Cardiovasc Imaging. 2013;6:560–567.
    1. Shukla AP, Kumar RB, Aronne LJ. Lorcaserin HCl for the treatment of obesity. Expert Opin Pharmacother. 2015;15:1–8.
    1. : A study to evaluate the effect of long-term treatment with BELVIQ (lorcaserin HCl) on the incidence of major adverse cardiovascular events and conversion to type 2 diabetes mellitus in obese and overweight subjects with cardiovascular disease or multiple cardiovascular risk factors (CAMELLIA-TIMI). (last accessed November 30, 2015).
    1. Singh J, Kumar R. Phentermine-topiramate: First combination drug for obesity. Int J Appl Basic Med Res. 2015;5:157–158.
    1. Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, Tam PY, Troupin B, Day WW. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP) Obesity (Silver Spring) 2012;20:330–342.
    1. Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, Day WW. Effects of low-dose, controlled release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341–1352.
    1. Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, Schwiers M, Day WW, Bowden CH. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo controlled, phase 3 extension study. Am J Clin Nutr. 2012;95:297–308.
    1. Aronne LJ, Wadden TA, Peterson C, Winslow D, Odeh S, Gadde KM. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. Obesity (Silver Spring) 2013;21:2163–2171.
    1. Jordan J, Astrup A, Engeli S, Narkiewicz K, Day WW, Finer N. Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity. J Hypertens. 2014;32:1178–1188.
    1. VIVUS Reports Topline Findings from FORTRESS. (media release on the internet). 21 December 2011. (last accessed November 30, 2015).
    1. Fujioka K. Sustained-release naltrexone/bupropion: a novel pharmacologic approach to obesity and food craving. US Endocrinology. 2014;10:53–58.
    1. Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, Kim DD, Dunayevich E, COR-I Study Group Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376:595–605.
    1. Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, Kim D, Dunayevich E, COR-II Study Group A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II) Obesity (Silver Spring) 2013;21:935–943.
    1. Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O'Neil PM, Perri MG, Pi-Sunyer FX, Rock CL, Erickson JS, Maier HN, Kim DD, Dunayevich E. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring) 2011;19:110–120.
    1. Hollander P, Gupta AK, Plodkowski R, Greenway F, Bays H, Burns C, Klassen P, Fujioka K, for The COR-Diabetes Study Group Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36:4022–4029.
    1. : Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects with Cardiovascular Risk Factors (The Light Study). (last accessed November 30, 2015).
    1. Holst JJ. Incretin hormones and the satiation signal. Int J Obes (Lond) 2013;37:1161–1168.
    1. Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME, Niskanen L, Rasmussen MF, Rissanen A, Rössner S, Savolainen MJ, Van Gaal L, NN8022–1807 Investigators Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 2012;36:843–854.
    1. Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771.
    1. Astrup A, Rossner S, Van Gaal L Rissanen A, Niskanen L, Al Hakim M, Madsen J, Rasmussen MF, Lean ME, NN8022–1807 Study Group Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374:1606–1616.
    1. Kim SH, Abbasi F, Lamendola C, Liu A, Ariel D, Schaaf P, Grove K, Tomasso V, Ochoa H, Liu YV, Chen YD, Reaven G. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care. 2013;36:3276–3282.
    1. Wadden TA, Hollander P, Klein S Niswender K, Woo V, Hale PM, Aronne L, NN8022–1923 Investigators Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond) 2013;37:1443–1451.
    1. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DCW, le Roux CW, Ortiz RV, Bjorn-Jensen C, Wilding JPH for the SCALE Obesity and Prediabetes NN8022–1839 Study Group A randomized controlled trial of 3.0 mg liraglutide in weight management. N Engl J Med. 2015;373:11–22.
    1. : Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results – A Long Term Evaluation (LEADER®). (last accessed November 30, 2015).
    1. Marso SP, Poulter NR, Nissen SE, Nauck MA, Zinman B, Daniels GH, Pocock S, Steinberg WM, Bergenstal RM, Mann JF, Ravn LS, Frandsen KB, Moses AC, Buse JB. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J. 2013;166:823–830.
    1. Daniels GH, Hegedüs L, Marso SP, Nauck MA, Zinman B, Bergenstal RM, Mann JFE, Karsbøl JD, Moses AC, Buse JB, Tuttle RM, on behalf of the LEADER trial investigators LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations. Diabetes Obes Metab. 2015;17:477–486.
    1. Lean ME, Carraro R, Finer N, Hartvig H, Lindegaard ML, Rössner S, Van Gaal L, Astrup A, NN8022–1807 Investigators Tolerability of nausea and vomiting, and associations with weight loss, in a randomized trial of liraglutide in obese, non-diabetic adults. Int J Obes (Lond) 2013;38:689–697.
    1. Pories WJ. Bariatric surgery: risks and rewards. J Clin Endocrinol Metab. 2008;93((suppl 1)):S89–S96.
    1. Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial – a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013;273:219–234.
    1. Berrington de Gonzalez A, Hartge P, Cerhan JR, Flint AJ, Hannan L, MacInnis RJ, Moore SC, Tobias GS, Anton-Culver H, Freeman LB, Beeson WL, Clipp SL, English DR, Folsom AR, Freedman DM, Giles G, Hakansson N, Henderson KD, Hoffman-Bolton J, Hoppin JA, Koenig KL, Lee IM, Linet MS, Park Y, Pocobelli G, Schatzkin A, Sesso HD, Weiderpass E, Willcox BJ, Wolk A, Zeleniuch-Jacquotte A, Willett WC, Thun MJ. Body-mass index and mortality among 1.46 million white adults. N Engl J Med. 2010;363:2211–2219.
    1. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA. 2013;309:71–82.
    1. Neovius M, Narbro K, Keating C, Peltonen M, Sjöholm K, Agren G, Sjöström L, Carlsson L. Health care use during 20 years following bariatric surgery. JAMA. 2012;308:1132–1141.
    1. Fried M, Yumuk Y, Oppert JM, Scopinaro N, Torres AJ, Weiner R, Yashkov Y, Frühbeck G. Interdisciplinary European guidelines on metabolic and bariatric surgery. Obes Facts. 2013;6:449–468.
    1. Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, Bantle JP, Sledge I. Weight and type 2 diabetes after bariatric surgery: systemic review and meta-analysis. Am J Med. 2009;122:248–256.
    1. Hofsø D, Nordstrand N, Johnson LK, Karlsen TI, Hager H, Jenssen T, Bollerslev J, Godang K, Sandbu R, Røislien J, Hjelmesaeth J. Obesity-related cardiovascular risk factors after weight loss: a clinical trial comparing gastric bypass surgery and intensive lifestyle intervention. Eur J Endocrinol. 2010;163:735–745.
    1. Hofsø D, Jenssen T, Bollerslev J Ueland T, Godang K, Stumvoll M, Sandbu R, Røislien J, Hjelmesæth J. Beta cell function after weight loss: a clinical trial comparing gastric bypass surgery and intensive lifestyle intervention. Eur J Endocrinol. 2011;164:231–238.
    1. Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Brethauer SA, Navaneethan SD, Aminian A, Pothier CE, Kim ESH, Nissen SE, Kashyap SR, for the STAMPEDE Investigators Bariatric surgery versus intensive medical therapy for diabetes – 3-year outcomes. N Engl J Med. 2014;370:2002–2013.
    1. DeMaria EJ. Bariatric surgery for morbid obesity. N Engl J Med. 2007;356:2176–2183.
    1. Sauerland S, Angrisani L, Belachew M, Chevallier JM, Favretti F, N Fingerhut A, Garcia Caballero M, Guisado Macias JA, Mittermair R, Morino M, Msika S, Rubino F, Tacchino R, Weiner R, Neugebauer EA, European Association for Endoscopic Surgery Obesity surgery: evidence based guidelines of the EAES. Surg Endosc. 2005;19:200–221.
    1. Ferraro DR. Preparing patients for bariatric surgery – the clinical considerations. Clin Rev. 2004;14:57–63.
    1. Reoch J, Mottillo S, Shimony A, Filion KB, Christou NV, Joseph L, Poirier P, Eisenberg MJ. Safety of laparoscopic vs open bariatric surgery: a systematic review and meta-analysis. Arch Surg. 2011;146:1314–1322.
    1. Korner J, Inabnet W, Febres G, Conwell IM, McMahon DJ, Salas R, Taveras C, Schrope B, Bessler M. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. Int J Obes (Lond) 2009;33:786–795.
    1. Laferrere B, Teixeira J, McGinty J, Tran H, Egger JR, Colarusso A, Kovack B, Bawa B, Koshy N, Lee H, Yapp K, Olivan B. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93:2479–2485.
    1. Bose M, Teixeira J, Olivan B, Bawa B, Arias S, Machineni S, Pi-Sunyer FX, Scherer PE, Laferrère B. Weight loss and incretin responsiveness improve glucose control independently after gastric bypass surgery. J Diabetes. 2010;2:47–55.
    1. Vidal J, Ibarzabal A, Romero F, Delgado S, Momblán D, Flores L, Lacy A. Type 2 diabetes mellitus and the metabolic syndrome following sleeve gastrectomy in severely obese subjects. Obes Surg. 2008;18:1077–1082.
    1. Leslie DB, Dorman RB, Serrot FJ, Swan TW, Kellogg TA, Torres-Villalobos G, Buchwald H, Slusarek BM, Sampson BK, Bantle JP, Ikramuddin S. Efficacy of the Roux-en-Y gastric bypass compared to medically managed controls in meeting the American Diabetes Association composite end point goals for management of type 2 diabetes mellitus. Obes Surg. 2012;22:367–374.
    1. Carlsson LM, Peltonen M, Ahlin S, Anveden Å, Bouchard C, Carlsson B, Jacobson P, Lönroth H, Maglio C, Näslund I, Pirazzi C, Romeo S, Sjöholm K, Sjöström E, Wedel H, Svensson PA, Sjöström L. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med. 2012;367:695–704.
    1. Arterburn DE, Bogart A, Sherwood NE, Sidney S, Coleman KJ, Haneuse S, OʼConnor PJ, Theis MK, Campos GM, McCulloch D, Selby J. A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg. 2013;23:93–102.
    1. Laferrere B. Effect of gastric bypass surgery on the incretins. Diabetes Metab. 2009;35:513–517.
    1. Kashyap SR, Daud S, Kelly KR, Gastaldelli A, Win H, Brethauer S, Kirwan JP, Schauer PR. Acute effects of gastric bypass versus gastric restrictive surgery on beta cell function and insulinotropic hormones in severely obese patients with type 2 diabetes. Int J Obes (Lond) 2010;34:462–471.
    1. Peterli R, Wolnerhanssen B, Peters T, Devaux N, Kern B, Christoffel-Courtin C, Drewe J, von Flüe M, Beglinger C. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg. 2009;250:234–241.
    1. Mingrone G, Castagneto-Gissey L. Mechanisms of early improvement/resolution of type 2 diabetes after bariatric surgery. Diabetes Metab. 2009;35:518–523.
    1. Briatore L, Salani B, Andraghetti G, Maggi D, Adami GF, Scopinaro N, Cordera R. Beta-cell function improvement after biliopancreatic diversion in subjects with type 2 diabetes and morbid obesity. Obesity (Silver Spring) 2010;18:932–936.
    1. Briatore L, Salani B, Andraghetti G, Danovaro C, Sferrazzo E, Scopinaro N, Adami GF, Maggi D, Cordera R. Restoration of acute insulin response in T2DM subjects 1 month after biliopancreatic diversion. Obesity (Silver Spring) 2008;16:77–81.
    1. Sampsel S, May J. Assessment and management of obesity and comorbid conditions. Dis Manag. 2007;1:252–265.
    1. Jordan J, Yumuk V, Schlaich M, Nilsson PM, Zahorska-Markiewicz B, Grassi G, Schmieder RE, Engeli S, Finer N. Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension. J Hypertens. 2012;30:1047–1055.
    1. Tsigos C, Hainer V, Basdevant A, Finer N, Mathus-Vliegen E, Micic D, Maislos M, Roman G, Schutz Y, Toplak H, Yumuk V, Zahorska-Markiewicz B, for the Obesity Management Task Force of the European Association for the Study of Obesity Criteria for EASO-collaborating centres for obesity management. Obes Facts. 2011;4:329–333.
    1. Scottish Intercollegiate Guidelines Network . Integrating Prevention with Weight Management. A National Clinical Guideline Recommended for Use in Scotland. Edinburgh: Scottish Intercollegiate Guidelines Network; 1996. Obesity in Scotland.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever